Literature DB >> 23893155

Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation.

Yuri Stanevsky1, Alexander Tsivian, Matvey Tsivian.   

Abstract

A new research study evaluated the mechanisms of prostate cancer (PCa) resistance to androgen deprivation therapy (ADT) and progression to castrate-resistant disease. Using a coclinical approach, the investigators were able to identify key genetic determinants of ADT resistance, gain insight into the molecular pathways that play a key role in this transition and propose a potential management strategy to overcome ADT resistance in select cancers. This represents a step forward towards personalized medicine guided by specific molecular markers of prostate cancer enabling more effective therapies targeted towards altered metabolic pathways.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23893155      PMCID： PMC3854062          DOI： 10.1038/aja.2013.96

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


  8 in total

1.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

Review 2.  Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.

Authors:  Rhonda L Bitting; Andrew J Armstrong
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

3.  Genetic markers associated with early cancer-specific mortality following prostatectomy.

Authors:  Wennuan Liu; Chunmei C Xie; Christopher Y Thomas; Seong-Tae Kim; Johan Lindberg; Lars Egevad; Zhong Wang; Zheng Zhang; Jishan Sun; Jielin Sun; Patrick P Koty; A Karim Kader; Scott D Cramer; G Steven Bova; S Lilly Zheng; Henrik Grönberg; William B Isaacs; Jianfeng Xu
Journal:  Cancer       Date:  2013-04-22       Impact factor: 6.860

Review 4.  Future prospects: who is the patient who still dies of prostate cancer following local treatment of high-risk prostate cancer? Can we prolong their lives using modern treatment approaches?

Authors:  Benjamin E Ayres; Prasanna Sooriakumaran
Journal:  Curr Opin Urol       Date:  2013-07       Impact factor: 2.309

Review 5.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.

Authors:  T Karantanos; P G Corn; T C Thompson
Journal:  Oncogene       Date:  2013-06-10       Impact factor: 9.867

6.  Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.

Authors:  Y W Francis Lam
Journal:  ISRN Pharmacol       Date:  2013-02-28

7.  A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Authors:  Andrea Lunardi; Ugo Ala; Mirjam T Epping; Leonardo Salmena; John G Clohessy; Kaitlyn A Webster; Guocan Wang; Roberta Mazzucchelli; Maristella Bianconi; Edward C Stack; Rosina Lis; Akash Patnaik; Lewis C Cantley; Glenn Bubley; Carlos Cordon-Cardo; William L Gerald; Rodolfo Montironi; Sabina Signoretti; Massimo Loda; Caterina Nardella; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2013-06-02       Impact factor: 38.330

8.  Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.

Authors:  Guocan Wang; Andrea Lunardi; Jiangwen Zhang; Zhenbang Chen; Ugo Ala; Kaitlyn A Webster; Yvonne Tay; Enrique Gonzalez-Billalabeitia; Ainara Egia; David R Shaffer; Brett Carver; Xue-Song Liu; Riccardo Taulli; Winston Patrick Kuo; Caterina Nardella; Sabina Signoretti; Carlos Cordon-Cardo; William L Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2013-06-02       Impact factor: 38.330
  8 in total
  1 in total

Review 1.  "Super-active surveillance": MRI ultrasound fusion biopsy and ablation for less invasive management of prostate cancer.

Authors:  Jonathan B Bloom; Samuel A Gold; Graham R Hale; Kareem N Rayn; Vikram K Sabarwal; Ivane Bakhutashvili; Vladimir Valera; Baris Turkbey; Peter A Pinto; Bradford J Wood
Journal:  Gland Surg       Date:  2018-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.